You are here: Industry Insights > Alector

News List

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting FirstWordPharma
November 04, 2021
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference...
GSK and Alector announce global collaboration in immuno-neurology worldpharmanews
July 05, 2021
GlaxoSmithKline plc and Alector, announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
Innovent, Alector Enter Oncology Alliance contractpharma
April 01, 2020
To develop and commercialize an anti-SIRP-alpha antibody (Alector's AL008) for the treatment of oncology indications in China.
Alector kicks off biotech IPOs after US government shutdown pharmaphorum
February 14, 2019
The 35-day US government shutdown has not just played havoc at government-run agencies – it has had a knock-on effect on the stock market because of cutbacks at the Securities and Exchange Commission financial regulator.
Alector raises $133m to advance Alzheimer’s disease drugs pharmaceutical-technology
July 30, 2018
Biotechnology firm Alector has raised $133m in a series E financing round to support further development of its clinical programmes and expand its discovery platform.